After nearly two years of all smoke, no fire around President Trump’s promise to curtail drug prices, there’s finally some glimmer of action. Pfizer said last week it would halt its price hikes, and Novartis and Merck took similar actions this week. But we still don’t know the details of the administration’s drug-pricing policy, if … Continue reading “Bio Roundup: Drug Prices, CRISPR Caveats, Rubius IPO Pop & More”
Category: New York
PTC Dives Into Gene Therapy with $50M Agilis Biotherapeutics Deal
PTC Therapeutics is looking to gene therapy in a bid to broaden its pipeline, scooping up privately held Agilis Biotherapeutics in a cash and stock deal. South Plainfield, NJ-based PTC (NASDAQ: [[ticker:PTCT]]) will pay $50 million up front, plus $150 million in PTC shares, for Agilis. Agilis, based in Cambridge, MA, could get up to … Continue reading “PTC Dives Into Gene Therapy with $50M Agilis Biotherapeutics Deal”
If the Shoe Fits: Luxury Shoe Club Launches E-Consignment Store
One in five pairs of shoes sit unworn in the average woman’s closet. So, why not sell these unused, or slightly used, pairs to someone who will wear them? That’s the view of Scott Van Valkenburgh, co-founder of Luxury Shoe Club, a Raleigh, NC-based startup that caters to women who want to buy and sell … Continue reading “If the Shoe Fits: Luxury Shoe Club Launches E-Consignment Store”
Google Partners With Zapata on Open-Source Quantum Computing Effort
Zapata Computing, a Harvard University spinout developing software to enable quantum computers, said Wednesday it’s working with Google to advance quantum computing technologies. Zapata said it’s one of the first users of Cirq, Google’s new open-source software framework for quantum computing. The initiative is yet another example of the growing investment in quantum computing research … Continue reading “Google Partners With Zapata on Open-Source Quantum Computing Effort”
Fresh Off Bristol Buyout, IFM Backers Raise $31M to Plot a Second Strike
Nearly one year ago, biotech startup IFM Therapeutics sold some of its assets to Bristol-Myers Squibb for $300 million. But IFM’s founders stuck around to try to capitalize on the startup’s remaining research. They’ve formed a Boston business, IFM Tre, that has just raised $31 million to fund some of that work. The cash comes … Continue reading “Fresh Off Bristol Buyout, IFM Backers Raise $31M to Plot a Second Strike”
E.U. Slaps $5B Antitrust Fine on Google; Trump Blasts Back With Tweet
[Updated 7/19/18, 9:59 am. See below.] If top European leaders faced a testy President Donald Trump in a series of meetings this summer, imagine the mood when the president of the European Commission arrives at the White House next Wednesday. President Trump and the European Union’s top executive officer, Jean-Claude Juncker, are slated to discuss … Continue reading “E.U. Slaps $5B Antitrust Fine on Google; Trump Blasts Back With Tweet”
Walmart, Microsoft Deepen Partnership as Both Grapple With Amazon
The enemy of my enemy is my friend—even in the retail and cloud computing businesses. So says retail giant Walmart (NYSE: [[ticker:WMT]]) as it announced this morning a five-year partnership with Microsoft (NASDAQ: [[ticker:MSFT]]) to use machine learning and other technologies, deepening an existing partnership between two of Amazon’s biggest rivals. “Whether it’s combined with our … Continue reading “Walmart, Microsoft Deepen Partnership as Both Grapple With Amazon”
New Ethics Code Urges Tech Firms and Coders To Avoid Harming Society
Selling a new Web-connected thermostat or other wired gizmo to consumers without a plan to deliver the necessary security patches is not only bad business—it’s unethical. So is failing to challenge a law or tech company rule that governs work on technology products, if that rule causes unjustifiable harms to people or the environment. Those … Continue reading “New Ethics Code Urges Tech Firms and Coders To Avoid Harming Society”
Best Friday Reads: Social Media Rules Us All, and Mints Billionaires
Humans have had a drastic physical evolution recently—one that has notably taken only a few years. While the evolution from hunched primates to homo sapiens took tens of millions of years, we needed only about a decade to develop an arched neck that is perennially looking down at a smartphone—presumably one with a social media … Continue reading “Best Friday Reads: Social Media Rules Us All, and Mints Billionaires”
Bio Roundup: Pfizer’s Prices, Novartis Cuts, Gene Therapy Guide & More
Drug price changes typically happen either at the start of the calendar year or the beginning of the third quarter. Such changes are routine for many companies, but Pfizer took an unusual step this week by rolling back scheduled price increases on 40 of its drugs. The change of plan happened after Pfizer (NYSE: [[ticker:PFE]]) … Continue reading “Bio Roundup: Pfizer’s Prices, Novartis Cuts, Gene Therapy Guide & More”
Broadcom Eyes CA Technologies for $19B After Trump Axed Qualcomm Bid
Semiconductor maker Broadcom, which ended its effort to buy competitor Qualcomm earlier this year, has a new target: New York-based business software maker CA Technologies. The pair announced Wednesday that Broadcom (NASDAQ: [[ticker:AVGO]]), which moved its headquarters from Singapore to San Jose, CA, earlier this year, plans to pay $18.9 billion in cash for CA … Continue reading “Broadcom Eyes CA Technologies for $19B After Trump Axed Qualcomm Bid”
With $112M Fund, Glasswing Looks to Drive East Coast A.I. Startups
In a sea of emerging tech venture funds, Glasswing Ventures is trying to stand out. The Boston firm announced today it has closed its debut investment fund at $112 million. That’s bigger than the “micro-VC” funds of the past decade, but much smaller than the mega-funds (often in the billion-dollar range) that have been raised … Continue reading “With $112M Fund, Glasswing Looks to Drive East Coast A.I. Startups”
E-Retail Startup Pointy Raises $12M, Helps Small Shops Be Found Online
Mark Cummins wondered why online search engines could help you locate a landmark halfway around the world in a second but couldn’t tell him whether the corner store had a craft beer he liked. That’s what led him to co-found Pointy, which makes a hardware device that enables small retailers to easily upload inventory onto … Continue reading “E-Retail Startup Pointy Raises $12M, Helps Small Shops Be Found Online”
Otsuka Ramps Up Its Antibody Game with $430M Visterra Acquisition
Otsuka Pharmaceutical is expanding its pipeline and U.S. reach with an agreement to acquire Waltham, MA, clinical-stage drug developer Visterra for $430 million in cash. The deal, announced Wednesday, comes nine months after Visterra closed a $46.7 million Series C round to finance clinical development of its antibody drug programs. That financing followed Visterra’s attempt … Continue reading “Otsuka Ramps Up Its Antibody Game with $430M Visterra Acquisition”
Hype―and Skepticism―Remains for Dell’s Return to the Public Market
Austin—The possibility that Dell might return to the public markets has been talked about for months, if not longer. It became more realistic in February, when the Round Rock, TX-based company told securities regulators it was considering a public offering or a reverse merger with VMware, the publicly traded company of which Dell owns 81 … Continue reading “Hype―and Skepticism―Remains for Dell’s Return to the Public Market”
Venture Funding Keeps Momentum Amid IPO Wave; Plus Q2’s Top 10 Deals
[Updated 7/12/18, 9:24 am. See below.] Last year, U.S. venture capital investments swelled to a level not seen since the dot-com era of the early 2000s. This year could be even bigger. Investors funneled $57.5 billion into U.S. companies through the first six months of 2018, according to the latest Venture Monitor report produced quarterly … Continue reading “Venture Funding Keeps Momentum Amid IPO Wave; Plus Q2’s Top 10 Deals”
Acceleron, Celgene Drug Shines in Phase 3 Test in Rare Blood Disorder
A drug from Celgene and Acceleron Pharma has met the main goals of a late-stage test as a treatment for a rare blood disorder, the second set of positive results that the partners have released for the drug in as many weeks. The latest announcement covered use of the drug, luspatercept, as a treatment for … Continue reading “Acceleron, Celgene Drug Shines in Phase 3 Test in Rare Blood Disorder”
Bio Roundup: Dunsire’s Danish, Price Hikes, Rare-Disease Race & More
[Corrected, 7/6/18, 1:26 pm. See below.] Xconomy was dumbstruck this week, and not by the fireworks overhead. Our friend and one of our earliest employees, San Diego editor Bruce Bigelow, died suddenly last weekend. Bruce covered everything—and everyone—in San Diego’s innovation scene, including the life sciences. Some of our favorite stories of his sprang from … Continue reading “Bio Roundup: Dunsire’s Danish, Price Hikes, Rare-Disease Race & More”
Apparel Brands Keep Up with Amazon Using Smart Factory Floor Software
The fashion industry has always prided itself on being cutting-edge. With technologies like the Internet of Things and analytics, apparel brands are now able to pivot more easily and frequently as styles change. Apparel makers “scrub social media, bringing up styles based on what people are wearing,” says Paul Magel, president of application solutions and … Continue reading “Apparel Brands Keep Up with Amazon Using Smart Factory Floor Software”
The Empathy Economy: Emotional Intelligence in Customer Service
The “empathy economy” will help define the new reality of human and machine interactions in the customer service industry. A takeoff on the sharing economy, the empathy economy will grow due to brand mania and increased automation in the workplace. Consumers are inundated by brands in their day-to-day lives, and these brands sometimes create personal … Continue reading “The Empathy Economy: Emotional Intelligence in Customer Service”
Automation Anywhere Scores $250M to Globalize Bot Workforce
Automation Anywhere, which supplies customers with armies of software robots to take over manual tasks such as insurance claims processing, announced today it raised $250 million in a first funding round that set its post-money valuation at $1.8 billion. The San Jose, CA-based company, begun in 2003 by four co-founders who bootstrapped its funding, has … Continue reading “Automation Anywhere Scores $250M to Globalize Bot Workforce”
In Celebration of Bruce Bigelow: Our Memories, His Playlist
[Updated, 7/5/18. See below] Bruce Victor Bigelow, editor of Xconomy San Diego, passed away Friday afternoon, June 29, at the age of 63. He had suddenly fallen ill less than a week earlier, after he returned to San Diego from a hiking trip in Utah. Our initial post about Bruce’s death is here. And the … Continue reading “In Celebration of Bruce Bigelow: Our Memories, His Playlist”
Study: Blood Test for Prostate Cancer Can Guide Therapy, Extend Lives
Blood tests for cancer, known as liquid biopsies, have become available in recent years to guide treatments for people already diagnosed. But how useful are they? A paper published last week in the journal JAMA Oncology makes the case that one such test, Oncotype DX AR-V7 Nucleus Detect, might be worth its $3,980 price tag. … Continue reading “Study: Blood Test for Prostate Cancer Can Guide Therapy, Extend Lives”
Xconomy Mourns the Loss of San Diego Editor Bruce Bigelow
[Updated, 7/5/18. See below] It is with profound sadness that we at Xconomy say goodbye to our longtime friend and editor of Xconomy San Diego, Bruce Bigelow. An outstanding journalist, colleague, and friend, and a fixture of the San Diego innovation scene, Bruce passed away today at age 63 after a brief illness. We are … Continue reading “Xconomy Mourns the Loss of San Diego Editor Bruce Bigelow”
Nanotech Liquidia Hops IPO Wave as Lead Drug Faces Late-Stage Test
Liquidia Technologies focuses on the small. Its method of producing nano-scale particles improves how a drug reaches its target in the body. Now the clinical-stage biopharmaceutical company is aiming for something big: an IPO to finance tests of a pair of drugs that use this drug delivery technology. Research Triangle Park, NC-based Liquidia filed the … Continue reading “Nanotech Liquidia Hops IPO Wave as Lead Drug Faces Late-Stage Test”
Best Reads for Casual Friday: Cybersecurity (And Some Amazon, Too)
You’ve made it to Friday—it’s time to take a step back, prepare for a relaxing weekend, and read a few stories about the endless ways in which your personal information can be stolen. OK, maybe it’s better to spin it like this: Here are some of the most interesting reads from this last week on … Continue reading “Best Reads for Casual Friday: Cybersecurity (And Some Amazon, Too)”
Bio Roundup: Big Bucks For Calico, Data Dumps & The IPO Wave Rolls On
If you’re running a privately held biotech, the time to go public is now. Clinical data already in hand or not, biotechs have charged to Wall Street at a record pace over the past two weeks, raising more than $1 billion in offerings that all met or exceeded their projected valuations. And there are no … Continue reading “Bio Roundup: Big Bucks For Calico, Data Dumps & The IPO Wave Rolls On”
Acceleron’s Blood Drug Hits Phase 3 Goals, Paves Way for FDA Filing
An experimental Acceleron drug for a blood disorder has hit the main goals of a pivotal study, and the company and partner Celgene say they now plan to file for FDA approval next year. The Acceleron (NASDAQ: [[ticker:XLRN]]) drug, luspatercept, is being tested as a treatment for myelodysplastic syndrome (MDS), a type of cancer characterized … Continue reading “Acceleron’s Blood Drug Hits Phase 3 Goals, Paves Way for FDA Filing”
EverQuote Founders Talk IPO Fever, Journey from Biotech to Insurance
When I got on the phone Thursday with the leaders of EverQuote, Boston’s newest publicly traded tech company, I expected them to grumble about how I cast their venture as a “company you’ve never heard of” in yesterday’s story about its IPO. On the contrary, EverQuote CEO and co-founder Seth Birnbaum agreed with me. The … Continue reading “EverQuote Founders Talk IPO Fever, Journey from Biotech to Insurance”
IPO Wave Rolls On as Five Life Science Firms Haul In $651M
A week after seven biotechs went public, setting a new record for the Nasdaq, five more life sciences companies have joined the club. The latest crop continued the positive momentum for life sciences offerings, as the group either met or exceeded their projections and raised a total of $651 million. Neon Therapeutics (NASDAQ: [[ticker:NTGN]]) was … Continue reading “IPO Wave Rolls On as Five Life Science Firms Haul In $651M”
Akebia Merges With Keryx as Anemia Drug Race Nears Finish Line
The race to treat anemia with a pill, not an injectable biologic, just took a new turn. Akebia Therapeutics (NASDAQ: [[ticker:AKBA]]), which is battling with FibroGen (NASDAQ: [[ticker:FGEN]]) to bring an anemia pill to market, has just announced plans to merge with kidney drug disease developer Keryx Pharmaceuticals (NASDAQ: [[ticker:KERX]]) in an all-stock deal that … Continue reading “Akebia Merges With Keryx as Anemia Drug Race Nears Finish Line”
BitSight Picks Up $60M to Fend Off Rivals in Cybersecurity Ratings
BitSight Technologies is restocking its war chest to try and win the emerging market for cybersecurity ratings. Today the Cambridge, MA-based tech company announced it raised $60 million in a Series D funding round led by Warburg Pincus, the global private equity firm that has backed the likes of CrowdStrike in cybersecurity, DBRS in credit … Continue reading “BitSight Picks Up $60M to Fend Off Rivals in Cybersecurity Ratings”
AstraZeneca’s PARP Drug Is First to Help New Ovarian Cancer Patients
Over the past few years, a new class of drugs known as “PARP” inhibitors has begun to change how ovarian cancer is treated. Data released by AstraZeneca and partner Merck this morning, from a Phase 3 study of the drug olaparib (Lynparza), could continue the trend. AstraZeneca (NYSE: [[ticker:AZN]]) and Merck (NYSE: [[ticker:MRK]]) said that … Continue reading “AstraZeneca’s PARP Drug Is First to Help New Ovarian Cancer Patients”
Don’t Be Boston 2.0, And Photos From “Bringing Back the Expats”
Be your own biotech cluster, not a Boston redux. Accelerate the momentum that’s already begun, don’t let it fizzle. And above all, be fearless entrepreneurs. You’ll need to be if New York biotech will ever become what its champions hope. Those were just a few lessons ex-New Yorker biopharma veterans had for the nascent life … Continue reading “Don’t Be Boston 2.0, And Photos From “Bringing Back the Expats””
Senators Grill HHS’s Azar on Drug Price Cuts That Have Yet to Come
When President Trump signed legislation last month allowing seriously ill patients the “right to try” unapproved drugs without FDA oversight, he voiced a bold prediction: Within two weeks, he said, drug companies would announce “voluntary massive drops in prices.” Asked for further detail, the Department of Health and Human Services (HHS) declined to elaborate on … Continue reading “Senators Grill HHS’s Azar on Drug Price Cuts That Have Yet to Come”
How the Rise of Beijing and Shanghai Tech May Impact Silicon Valley
When it comes to startup tech hubs, U.S. cities from San Francisco to Austin to Boston come first to mind. But that is starting to change, as Asian cities—particularly in China—are snapping up more tech venture capital funding and exits, according to a new report from CB Insights. Silicon Valley tech startups pulled in the … Continue reading “How the Rise of Beijing and Shanghai Tech May Impact Silicon Valley”
As Cybersecurity Business Expands, Proficio Offers Risk Scoring
In a bid to differentiate itself from the crowd of cybersecurity companies offering network monitoring services, Carlsbad, CA-based Proficio said it has developed a risk-scoring system that assesses its customers’ network security controls. In addition to highlighting each customer’s vulnerabilities to cyber-attack, Proficio said its new ThreatInsight software dashboard offers recommendations on how a customer … Continue reading “As Cybersecurity Business Expands, Proficio Offers Risk Scoring”
Stitch Fix CTO Polinsky Says Its Style Shuffle Game Makes Data Fun
When Cathy Polinsky became chief technology officer of Stitch Fix in late 2016, she knew one of the San Francisco-based company’s key challenges was continually refining its core software algorithm to make sure customers received the right tailored suggestions in their monthly wardrobe boxes. So, she made it into a game. Style Shuffle is a … Continue reading “Stitch Fix CTO Polinsky Says Its Style Shuffle Game Makes Data Fun”
With AppNexus Acquisition, AT&T Stakes Claim in Adtech, Analytics
[Updated 3:51 p.m. See Below.] AT&T is buying advertising tech company AppNexus in a deal reportedly worth around $1.6 billion. The telecom giant plans to add AppNexus to an advertising and analytics business that it created last year. The purchase shows AT&T’s (NYSE: [[ticker:T]]) interest in better utilizing its vast amounts of customer data so … Continue reading “With AppNexus Acquisition, AT&T Stakes Claim in Adtech, Analytics”
Akero Closes $65M Financing to Back Liver Drug Licensed from Amgen
New biotech startup Akero Therapeutics debuted Monday with $65 million in a Series A round of funding to advance clinical development of a drug for the fatty liver disease nonalcoholic steatohepatitis (NASH). Cambridge, MA-based Akero licensed the drug from Amgen (NASDAQ: [[ticker:AMGN]]), which had tested it in Phase 1 studies. Akero said Monday it will … Continue reading “Akero Closes $65M Financing to Back Liver Drug Licensed from Amgen”
With Roche Data, Cancer Combos Post First Win Vs. Small Cell Lung Cancer
Cancer immunotherapy combinations continue to chalk up wins against lung cancer. For the first time, an immunotherapy-chemotherapy combination has succeeded in a late-stage study of patients with small cell lung cancer (SCLC), a particularly aggressive form of the disease often linked to smoking. Roche’s South San Francisco, CA-based Genentech division said today that in a … Continue reading “With Roche Data, Cancer Combos Post First Win Vs. Small Cell Lung Cancer”
Some of the Best Reads for Casual Friday: Artificial Intelligence
Fridays can be the most productive work day, as you look to shore up everything before the weekend starts. Or, maybe instead, it’s a day filled with long lunches and listless Internet surfing, as you seek out all the interesting articles you missed during the week. Fear not: Xconomy has done the work for you, … Continue reading “Some of the Best Reads for Casual Friday: Artificial Intelligence”
Bio Roundup: Duchenne Data, Roche Buys Foundation, IPO Wave & More
Biotech financing is a cyclical thing. Two years ago, the IPO window was unlatched but a number of companies ended up withdrawing their stock offerings. Others that pushed their IPOs through couldn’t sell shares at the price they wanted. This year, the IPO window is wide open. A total of 93 IPOs have priced as … Continue reading “Bio Roundup: Duchenne Data, Roche Buys Foundation, IPO Wave & More”
Intel CEO Resigns After Board Learns of His Relationship With Employee
Intel (NASDAQ: [[ticker:INTC]]) announced Thursday that CEO Brian Krzanich has resigned in the wake of the company’s recent discovery that he had been involved in a past consensual relationship with an Intel employee. The relationship violated Intel’s non-fraternization policy—the finding of an ongoing investigation by internal and external counsel, the company said in a written … Continue reading “Intel CEO Resigns After Board Learns of His Relationship With Employee”
Latticework Launches Personal Hybrid Cloud for Private Data-Sharing
Were you aghast at revelations that third-party organizations were able to capture millions of Facebook profiles from users who were unaware of the company’s privacy policy terms? If so, a Silicon Valley startup is hoping to entice you with a new option for private data storage of your personal digital life, along with private channels … Continue reading “Latticework Launches Personal Hybrid Cloud for Private Data-Sharing”
Bio IPO Madness: Six Biotech Startups Raise $568M in 24 Hours
The window for biotech IPOs remains wide open and six more companies have charged through it, raising more than $568 million in the span of 24 hours. The first was Eidos Therapeutics (NASDAQ: [[ticker:EIDX]]), which raised $106 million in its stock market debut. The San Francisco company priced its IPO late Tuesday, selling 6.25 million … Continue reading “Bio IPO Madness: Six Biotech Startups Raise $568M in 24 Hours”
New Amazon-Led Healthcare Venture Taps Surgeon, Author Gawande as CEO
The new, independent, healthcare-focused company Amazon, Berkshire Hathaway, and JPMorgan Chase plan to launch made a big splash when it was first announced in January, but few details have emerged since. On Wednesday, the trio of American business heavyweights revealed a little more. They said Atul Gawande, a surgeon and author who is well known … Continue reading “New Amazon-Led Healthcare Venture Taps Surgeon, Author Gawande as CEO”
New Chapter: Publishing Executive Alston Becomes New CEO at DEC
Dallas—Alyce Alston, a veteran of the digital media and publishing industries, officially took over the reins of the Dallas Entrepreneur Center Wednesday. “I’ve always been an innovator within large organizations and then with startups after that,” she says. “I have a real empathy for startups, for entrepreneurs, people who are creating and doing things that … Continue reading “New Chapter: Publishing Executive Alston Becomes New CEO at DEC”
CrowdStrike Hauls In $200M, Reports Valuation Over $3 Billion
CrowdStrike, a Silicon Valley cybersecurity company that fends off hackers by patrolling the edge devices connected to a network, announced today it raised $200 million in a financing round that sets the company’s valuation at more than $3 billion. Sunnyvale, CA-based CrowdStrike, as an endpoint protection and response platform, uses next-generation antivirus software, scans for … Continue reading “CrowdStrike Hauls In $200M, Reports Valuation Over $3 Billion”
LoftSmart Adds $12.9M for Student Housing Review and Rental Software
LoftSmart, a website that helps college students find off-campus housing, has raised $12.9 million in an equity funding round, according to a securities filing. New York-based LoftSmart lets students search for and review properties typically rented by students, leaving feedback in each apartment building’s listing on amenities, problems, or other details that might help college … Continue reading “LoftSmart Adds $12.9M for Student Housing Review and Rental Software”